Fatty liver disease is increasingly common in Malaysia, closely tied to rising rates of obesity, type 2 diabetes, and metabolic syndrome. Many people discover they have it incidentally, through a routine ultrasound or blood test, with no symptoms at all. This guide explains current terminology, how risk is assessed, what standard management looks like, and what current regenerative research can and cannot currently offer for this specific condition.
Understanding MASLD Terminology
If you’ve researched fatty liver disease before, you may have come across several different, sometimes confusing, terms. Medical terminology in this area has shifted in recent years toward more precise language.
| Term | What It Means |
| NAFLD (Non-Alcoholic Fatty Liver Disease) | Older terminology, still widely used and understood |
| MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) | Updated, preferred terminology reflecting the metabolic basis of the condition |
| MASH (Metabolic dysfunction-Associated Steatohepatitis) | A more advanced form involving liver inflammation and cell damage, previously called NASH |
| Simple steatosis | Fat accumulation in the liver without significant inflammation or damage |
This terminology shift isn’t just academic, it reflects a clearer understanding that fatty liver disease is fundamentally linked to metabolic health, insulin resistance, obesity, and related conditions, rather than being a standalone liver problem.
Fatty Liver Disease Risk Assessment
Fatty liver disease doesn’t develop in isolation. It’s strongly associated with a cluster of metabolic risk factors common in the Malaysian population.
Key risk factors include:
- Overweight or obesity, particularly central/abdominal obesity
- Type 2 diabetes or insulin resistance
- High triglycerides or abnormal cholesterol levels
- High blood pressure
- Metabolic syndrome (a combination of the above factors)
- Sedentary lifestyle and diet high in processed foods and sugar
How risk and severity are typically assessed:
- Liver function blood tests, though these can appear normal even with significant fatty liver present
- Ultrasound imaging, commonly the first-line tool to detect fat accumulation in the liver
- FibroScan (transient elastography), assessing both fat content and liver stiffness, which helps estimate scarring (fibrosis) risk
- Blood-based fibrosis scoring tools (such as FIB-4), used to help estimate risk of more advanced liver scarring
- Liver biopsy, reserved for cases where more definitive staging is needed
Standard Management of Fatty Liver Disease
Management of fatty liver disease centres almost entirely on addressing the underlying metabolic drivers, since there is currently no medication universally approved specifically to reverse the condition.
| Approach | Purpose |
| Weight loss (gradual, sustained) | The single most effective intervention; even 7–10% body weight loss can meaningfully reduce liver fat |
| Dietary changes | Reducing refined sugar, processed food, and excess calorie intake |
| Regular physical activity | Improves insulin sensitivity and supports weight management |
| Managing diabetes and cholesterol | Treating underlying metabolic conditions directly |
| Limiting alcohol | Reduces additional liver stress, even in non-alcohol-related fatty liver |
| Emerging medications | Certain newer medications are being studied and, in some cases, approved for more advanced forms (MASH) in select markets |
.
Monitoring Fatty Liver Disease Assessment
Because fatty liver disease can progress silently toward fibrosis, cirrhosis, or, in a smaller proportion of cases, liver cancer, ongoing monitoring matters even when you feel completely well.
Typical monitoring includes:
- Periodic liver function tests, usually every 6 to 12 months depending on risk level
- Repeat imaging or FibroScan, to track changes in liver fat and stiffness over time
- Metabolic monitoring, including blood sugar, lipid profile, and weight trends
- Reassessment of fibrosis risk scores periodically, particularly if risk factors change
Monitoring frequency should be individualised based on your specific risk factors and findings, ideally guided by a hepatologist or physician familiar with your full history.
When to See a Hepatologist
Not every fatty liver finding requires specialist referral, but certain signs suggest it’s time to see a hepatologist rather than continuing with general monitoring alone:
- Elevated or rising liver enzymes on repeat testing
- A FibroScan or fibrosis score indicating significant scarring risk
- Known MASH (inflammation-related fatty liver) rather than simple steatosis
- Coexisting viral hepatitis or other liver conditions
- A family history of liver disease or liver cancer
- Any symptoms suggesting more advanced liver involvement, such as unexplained fatigue, abdominal discomfort, or jaundice
Early specialist input, before the condition progresses to cirrhosis, generally offers the most options for effectively managing the disease course.
Role and Limits of Research
Regenerative medicine research, including mesenchymal stem cell studies, has begun exploring fatty liver disease and its more advanced form, MASH, largely in preclinical and very early clinical settings.
What early research is exploring:
- Potential anti-inflammatory and metabolic effects of MSCs in liver tissue models
- Whether cell-based approaches might support a healthier liver environment alongside standard metabolic management
What current evidence does not establish:
- No regulatory authority has approved stem cell therapy specifically for fatty liver disease or MASH
- There is no established evidence that stem cell therapy reverses fat accumulation or fibrosis in this condition
- Lifestyle and metabolic management remain the only well-established, evidence-backed interventions at this time
23C Regen’s current treatable conditions list centres on more established research areas such as liver cirrhosis, where more clinical evidence exists. If you have early-stage fatty liver disease, the most valuable next step is usually metabolic risk management and monitoring, discussed below, rather than a cell therapy assessment.
Why Early Action Matters in Fatty Liver Disease
Fatty liver disease sits at a genuinely useful decision point. Caught and addressed early, through weight management, dietary change, and treatment of underlying metabolic conditions, it can often improve significantly or even resolve. Left unaddressed over years, particularly if it progresses to MASH with ongoing inflammation, it can advance toward fibrosis and eventually cirrhosis, a stage that is far harder to reverse. This is really the core message worth taking from current evidence: the most valuable intervention available right now for fatty liver disease isn’t a procedure or emerging therapy, it’s consistent, sustained metabolic management, started as early as possible.
Questions Worth Discussing With Your Doctor before Fatty Liver Disease Assessment
- What stage is my fatty liver disease at, and how was that determined?
- What specific, achievable lifestyle changes would make the most difference for me?
- How often should I be monitored, given my individual risk factors?
- Do I need a referral to a hepatologist at this stage?
- Is regenerative research relevant to my situation currently, or is lifestyle management the appropriate focus for now?
If you’d like to discuss your liver health more broadly, including whether an assessment for related conditions such as cirrhosis may be relevant to your situation, you’re welcome to get in touch
Frequently Asked Questions
Is fatty liver disease the same as liver cirrhosis?
No. Fatty liver disease is an earlier, often reversible stage. Cirrhosis is advanced, usually permanent scarring that can develop if fatty liver disease progresses untreated over years.
Can fatty liver disease be reversed?
Simple fatty liver (steatosis) can often improve significantly with sustained weight loss and lifestyle changes. More advanced fibrosis is harder to reverse.
Do I need a biopsy to diagnose fatty liver disease?
Not usually. Ultrasound and FibroScan are commonly used first, with biopsy reserved for cases needing more definitive staging or diagnosis.
Is stem cell therapy available for fatty liver disease at 23C Regen?
Not currently as a standard offering. Evidence in this specific condition remains early-stage; our established programmes focus on more researched areas like cirrhosis.
How much weight loss is needed to improve fatty liver disease?
Research suggests even 7–10% sustained body weight loss can meaningfully reduce liver fat and improve related metabolic markers in many patients.
Can I have fatty liver disease without being overweight?
Yes, it can occur in people of normal weight, particularly with insulin resistance or other metabolic risk factors, though it’s more common with excess weight.